CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cipla Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cipla Ltd
Mumbai Central
Phone: +91 2224826000p:+91 2224826000 MUMBAI, 400013  India Ticker: CIPLACIPLA
Business Summary
Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes---Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Yusuf K.Hamied 87 1/1/2016 1/1/1976
Global Chief Executive Officer, Managing Director, Executive Director UmangVohra 52 9/1/2016 8/12/2016
Global Chief Financial Officer AshishAdukia 8/16/2022 8/16/2022
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Cipla Medpro South Africa Limited Rosen Heights, Pasita Street, Bellville CAPE TOWN South Africa
Cipla U.S.A. Inc. 1560 Sawgrass Corporate Parkway Miami FL United States
InvaGen Pharmaceuticals, Inc. Hauppauge NY United States

Business Names
Business Name
500087
Actor Pharma (Pty) Ltd
Anmaraté (Pty) Limited
55 additional Business Names available in full report.

General Information
Number of Employees: 27,764 (As of 3/31/2024)
Outstanding Shares: 807,612,508 (As of 11/15/2024)
Shareholders: 445,004
Stock Exchange: NSE
Fax Number: +91 2224826120


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024